Abstract
The aim of this health technology assessment is to assess the clinical-effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of moderate to severe hepatitis C was appraised by NICE in 2004 (TA751) and an appraisal specifically for mild hepatitis C was carried out in 2006 (TA1062). Both appraisals were based on independent assessment reports conducted by SHTAC.3,4 Since NICE's clinical guidance was published, there have been extensions to the licences for peginterferon alfa-2a and -2b. This health technology assessment is a part-review of the current NICE guidance and will be restricted to the patient subgroups that are affected by the licence extensions for the peginterferons. This includes people who have been previously treated with peginterferon alfa and ribavirin in combination and who either did not respond or who responded but relapsed, people who meet the licensed criteria for receiving shortened courses of combination therapy and people with HCV/HIV co-infection The HTA Programme commissioned this technology assessment report on behalf of the National Institute for Health and Clinical Excellence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
